Keyword: Genzyme

Analysts previously predicted Cablivi (caplacizumab) could be the standard of care for aTTP, with peak global sales at $500 million.

Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.

The decision by two leading pharmacy benefit managers to exclude Sanofi's big-sellers in diabetes took a toll in 2017.

Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.

Sanofi is recalling a lot of its injected gel for treating arthritis in knees in the U.S. which has tested positive for microbial contamination.

The newest stop on the film festival circuit is one with entries that are all about rare diseases.

Three months ago, England’s cost watchdogs nixed Sanofi's Gaucher treatment Cerdelga. But they're already singing a different tune.

Sanofi’s vaccines business leaned on strong performances from pediatric, flu and travel shots on the way to 13.2% growth in Q1.

Biogen's Spinraza raised eyebrows for a $750,000 first-year price, but rare disease medications are expensive, period. Check out this list.

Sanofi is in talks to buy Flexion Therapeutics, a biotech with its lead product awaiting FDA approval, for more than $1 billion, according to a source close to the deal